Table 2.
Variable | WT-SED | WT-EX | FGF21KO-SED | FGF21KO-EX |
---|---|---|---|---|
FGF21, pg/ml | 892.50 ± 199.63 | 858.60 ± 130.97 | BDL | BDL |
Insulin, ng/ml | 1.23 ± 0.10 | 0.82 ± 0.08† | 2.61 ± 0.29* | 1.95 ± 0.23†* |
Glucose, mg/dl | 280.20 ± 10.75 | 280.53 ± 15.77 | 332.22 ± 21.89* | 350.84 ± 13.21* |
β-Hydroxybutyrate, μmol/l | 41.64 ± 4.29‡ | 28.04 ± 2.69† | 27.12 ± 2.38* | 24.04 ± 2.13†* |
Adiponectin, μg/ml | 21.38 ± 1.05 | 18.10 ± 0.64† | 20.17 ± 0.92 | 17.85 ± 0.49† |
TG, mg/dl | 61.06 ± 4.69 | 47.33 ± 2.10† | 64.44 ± 3.91 | 57.89 ± 2.53† |
Cholesterol, mg/dl | 95.37 ± 4.96 | 91.42 ± 1.90 | 111.51 ± 4.28* | 99.10 ± 4.28* |
FFA, μM | 769.44 ± 53.55 | 598.89 ± 32.73† | 813.11 ± 26.14 | 680.22 ± 35.05† |
Values are means ± SE (n = 9–15).
Significant genotype main effect (P ≤ 0.05);
significant exercise main effect (P ≤ 0.05);
significant differences vs.
WT-EX and FGF21KO-SED (P ≤ 0.05). BDL, below detectable limits; TG, triglyceride; FFA, free fatty acid.